Exelixis (EXEL) Cash from Financing Activities (2010 - 2026)

Exelixis' (EXEL) quarterly Cash from Financing Activities came in at -$457.1 million in Q2 2026, down 55.05% year-on-year from -$1.0 billion in Q2 2025, and down 79.56% quarter-over-quarter from -$254.6 million in Q1 2026.

Exelixis (EXEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Exelixis' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$457.1 million for Q2 2026.

  • On a quarterly basis, Cash from Financing Activities fell 55.05% year-over-year to -$457.1 million in Q2 2026; TTM through Apr 2026 was -$1.1 billion, a 53.04% decrease from a year earlier, with the FY2026 full-year figure at -$969.6 million, down 54.2% from the prior year.
  • Cash from Financing Activities slipped to -$457.1 million in Q2 2026 per EXEL's latest filing, from -$254.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $5.7 million in Q3 2024 and bottomed at -$457.1 million in Q2 2026.
  • The 5-year median for Cash from Financing Activities is -$184.0 million (2024), against an average of -$153.0 million.
  • Biggest YoY gain for Cash from Financing Activities was 2137.07% in 2023; the steepest drop was 10678.85% in 2023.
  • Year by year, Cash from Financing Activities stood at -$2.0 million in 2022, then sank by 10193.21% to -$206.2 million in 2023, then surged by 102.76% to $5.7 million in 2024, then plunged by 1923.38% to -$103.9 million in 2025, then plunged by 340.12% to -$457.1 million in 2026.
  • Per Business Quant, the three latest EXEL Cash from Financing Activities figures stand at -$457.1 million (Q2 2026), -$254.6 million (Q1 2026), and -$103.9 million (Q4 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 Exelixis 14.38 Bn 13.60 Bn 590.86 Mn -457.11 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 -457.11 Mn
Apr 3, 2026 -457.11 Mn
Jan 2, 2026 -254.57 Mn
Jan 2, 2026 -254.57 Mn
Oct 3, 2025 -103.86 Mn
Oct 3, 2025 -103.86 Mn
Jul 4, 2025 -316.34 Mn
Jul 4, 2025 -316.34 Mn
Apr 4, 2025 -294.82 Mn
Apr 4, 2025 -294.82 Mn
Jan 3, 2025 -188.03 Mn
Jan 3, 2025 -188.03 Mn
Sep 27, 2024 5.70 Mn
Sep 27, 2024 5.70 Mn
Jun 28, 2024 -262.42 Mn
Jun 28, 2024 -262.42 Mn
Mar 29, 2024 -184.05 Mn
Mar 29, 2024 -184.05 Mn
Dec 29, 2023 -206.17 Mn
Dec 29, 2023 -206.17 Mn